{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T12:13:01Z","timestamp":1784031181250,"version":"3.55.0"},"reference-count":21,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Acromegaly is caused by excessive growth hormone (GH) and insulin-like growth factor 1 (IGF1). Medical therapy plays a role as a treatment option for persistent disease after non-curative surgery or as a first-line therapy when surgery is not feasible. Pasireotide-LAR (Pas-LAR) is recommended for patients with acromegaly as second-line treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Aim<\/jats:title><jats:p>To evaluate the patients characteristics predictive of an adequate response to Pas-LAR and the long-term efficacy and safety of the Pas-LAR treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Data from 19 patients with active acromegaly, who were and resistant or intolerant to first-line medical therapy and were switched to pas-LAR have been retrospectively collected. We compared the baseline clinical and biochemical characteristics of patients who were found to respond to Pas-LAR therapy (responders, n=14) with those of patients who did not respond (non-responders, n=5). We then evaluated the Pas-LAR efficacy and safety during long-term follow-up in responders.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>IGF1 normalization occurred in 71.4% of responders after one injection. IGF1 levels, [median(interquartile range) of the upper limit of the normal range (ULN) fold increase] were higher in non-responders compared to responders within the initial month of therapy [1.40(1.30-2.34) vs 0.70(0.55-1.25), respectively, p=0.009] and after three [1.77(1.74-2.29) vs 0.94(0.82-1.13), respectively, p=0.029] and six months [1.68(1.33-1.72) vs 1.00(0.65 -1.28), respectively, p=0.002]. Out of 6 patients with symptomatic headache (all in responder group), 5 and 1 reported the resolution and improvement of headache, respectively, already after the first injection. Median HbA1c levels tended to increase from baseline to 6 months both in responder (36 mMol\/Mol to 42 mMol\/Mol) and non-responder patients (45 mMol\/Mol to 48 mMol\/Mol). During long term follow up, in the responder group 2 new patients developed diabetes. Tumor shrinkage was observed in 6 out of 7 evaluated responders, with no cases of size increase during the long-term follow-up.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Pas-LAR is effective and safe and the early identification of responders is possible just after the first administration.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fendo.2024.1344728","type":"journal-article","created":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T04:31:05Z","timestamp":1706761865000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["Efficacy of pasireotide LAR for acromegaly: a prolonged real-world monocentric study"],"prefix":"10.3389","volume":"15","author":[{"given":"Vittoria","family":"Favero","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedetta","family":"Zampetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuela I.","family":"Carioni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Dalino Ciaramella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erika","family":"Grossrubatscher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Dallabonzana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iacopo","family":"Chiodini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renato","family":"Cozzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,2,1]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/s41574-018-0058-5","article-title":"A consensus statement on acromegaly therapeutic outcomes","volume":"14","author":"Melmed","year":"2018","journal-title":"Nat Rev Endocrinol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-19-0762","article-title":"Acromegaly. Nature reviews disease primers 5(1). 2020. Pasireotide for acromegaly: long-term outcomes from an extension to the phase III PAOLA study","volume":"182","author":"Colao","year":"2019","journal-title":"Eur J Endocrinol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2018.00358","article-title":"Diabetes secondary to acromegaly: physiopathology, clinical features and effects of treatment","volume":"9","author":"Ferra\u00f9","year":"2018","journal-title":"Front Endocrinol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11102-020-01091-7","article-title":"A pituitary society update to acromegaly management guidelines","volume":"24","author":"Fleseriu","year":"2021","journal-title":"Pituitary"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2014-2700","article-title":"Acromegaly: an endocrine society clinical practice guideline","volume":"99","author":"Katznelson","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1007\/s11154-020-09588-z","article-title":"Multidisciplinary management of acromegaly: A consensus","volume":"21","author":"Giustina","year":"2020","journal-title":"Rev Endocr Metab Disord"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.648411","article-title":"Pasireotide in the personalized treatment of acromegaly","volume":"12","author":"Puig-Domingo","year":"2021","journal-title":"Front Endocrinol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1530\/EJE-19-0762","article-title":"Pasireotide for acromegaly: long-term outcomes from an extension to the Phase III PAOLA study","volume":"182","author":"Colao","year":"2020","journal-title":"Eur J Endocrinol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(14)70169-X","article-title":"Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial","volume":"2","author":"Gadelha","year":"2014","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1007\/s11154-022-09710-3","article-title":"Pasireotide\u2014a novel somatostatin receptor ligand after 20 years of use","volume":"23","author":"Bolanowski","year":"2022","journal-title":"Rev Endocr Metab Disord"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-023-01360-1","article-title":"Acromegaly Consensus Group. Consensus on criteria for acromegaly diagnosis and remission","author":"Giustina","year":"2023","journal-title":"Pituitary"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgad378","article-title":"Long-term efficacy and safety of pasireotide in patients with acromegaly: 14 years of single-center real-world experience","volume":"108","author":"Gadelha","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"key":"B13","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1007\/s12020-021-02782-2","article-title":"Long-term safety and efficacy of long-acting pasireotide in acromegaly","volume":"74","author":"Akirov","year":"2021","journal-title":"Endocrine"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-023-03325-7","article-title":"De-escalation treatment with pasireotide for acromegaly: A long-term experience","volume":"80","author":"Giampietro","year":"2023","journal-title":"Endocrine"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1530\/EC-23-0155","article-title":"Long-term, real-world experience of pasireotide dose reduction in patients with acromegaly","volume":"12","author":"Marques","year":"2023","journal-title":"Endocr Connect"},{"key":"B16","doi-asserted-by":"publisher","first-page":"84","DOI":"10.14310\/horm.2002.1722","article-title":"Somatotropinomas inadequately controlled with octreotide may over-respond to pasireotide: the importance of dose adjustment to achieve long-term biochemical control","volume":"16","author":"Shimon","year":"2017","journal-title":"Hormones"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-016-0734-1","article-title":"Hyperglycemia induced by pasireotide in patients with cushing\u2019s disease or acromegaly","volume":"19","author":"Silverstein","year":"2016","journal-title":"Pituitary"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2018-01979","article-title":"How to position pasireotide LAR treatment in acromegaly","volume":"104","author":"Coopmans","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-021-01185-w","article-title":"Real-world experience with pasireotide-LAR in resistant acromegaly: A single center 1-year observation","volume":"25","author":"Stelmachowska-Bana\u015b","year":"2022","journal-title":"Pituitary"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ghir.2015.07.003","article-title":"Truncated somatostatin receptor 5 may modulate therapy response to somatostatin analogues - observations in two patients with acromegaly and severe headache","volume":"25","author":"Marina","year":"2015","journal-title":"Growth Hormone IGF Res"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.arcmed.2023.102924","article-title":"Predictors of response to treatment with first-generation somatostatin receptor ligands in patients with acromegaly","volume":"54","author":"Marques-Pamies","year":"2023","journal-title":"Arch Med Res"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2024.1344728\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T04:31:08Z","timestamp":1706761868000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2024.1344728\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,1]]},"references-count":21,"alternative-id":["10.3389\/fendo.2024.1344728"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2024.1344728","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,1]]},"article-number":"1344728"}}